 Goosalcumab, an Illinois, 23 inhibitor, effectively treats moderate to severe plaque psoriasis and provides greater efficacy than succukinumab, Illinois, 17a inhibitor, in most sub-populations of patients with psoriasis. This article was authored by Andrew Bloorvelt, April W. Armstrong, Richard G. Langley, and others.